Journal
CLINICAL CANCER RESEARCH
Volume 20, Issue 20, Pages 5147-5149Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-0820
Keywords
-
Categories
Funding
- NIH/National Institute of Neurological Disorders and Stroke (NINDS) [U01-NS052465, U01-NS052465-S1, R01-NS074387, R01-NS057711]
- NIH/NINDS [R01-NS054193, R01-NS061107, R01-NS082311, R21-NS084275]
- Department of Neurosurgery at the University of Michigan School of Medicine
Ask authors/readers for more resources
Immunosuppressive checkpoints mediated by IDO, CTLA4, and PD1/PDL1 play a critical role in glioma progression and the efficacy of immunotherapies. Combined blockade of these immunosuppressive checkpoints in a glioma model elicited long-term survival. This combined blockade adds to the armamentarium of anti-glioma therapies, which could be implemented in clinical trials. (C)2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
